<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To identify rational therapeutic combinations with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (Ara-C), we developed a high-throughput, small-interference <z:chebi fb="40" ids="33697">RNA</z:chebi> (siRNA) platform for myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Of 572 kinases individually silenced in combination with Ara-C, silencing of 10 (1.7%) and 8 (1.4%) kinases strongly increased Ara-C activity in TF-1 and <z:chebi fb="0" ids="46941">THP</z:chebi>-1 cells, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>The strongest molecular concepts emerged around kinases involved in cell-cycle checkpoints and DNA-damage repair </plain></SENT>
<SENT sid="3" pm="."><plain>In confirmatory siRNA assays, inhibition of WEE1 resulted in more potent and universal sensitization across myeloid cell lines than siRNA inhibition of PKMYT1, CHEK1, or ATR </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment of 8 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) cell lines with commercial and the first-in-class clinical WEE1 kinase inhibitor MK1775 confirmed sensitization to Ara-C up to 97-fold </plain></SENT>
<SENT sid="5" pm="."><plain>Ex vivo, adding MK1775 substantially <z:mp ids='MP_0010831'>reduced viability</z:mp> in 13 of 14 AML, <z:mp ids='MP_0005481'>CML</z:mp>, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patient samples compared with Ara-C alone </plain></SENT>
<SENT sid="6" pm="."><plain>Maximum sensitization occurred at lower to moderate concentrations of both drugs </plain></SENT>
<SENT sid="7" pm="."><plain>Induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was increased using a combination of Ara-C and MK1775 compared with using either drug alone </plain></SENT>
<SENT sid="8" pm="."><plain>WEE1 is expressed in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, ALL, and <z:mp ids='MP_0005481'>CML</z:mp> specimens </plain></SENT>
<SENT sid="9" pm="."><plain>Data from this first siRNA-kinome sensitizer screen suggests that inhibiting WEE1 in combination with Ara-C is a rational combination for the treatment of myeloid and <z:hpo ids='HP_0005526'>lymphoid leukemias</z:hpo> </plain></SENT>
</text></document>